Your browser doesn't support javascript.
loading
Low-dose (7.5 mg/kg) bevacizumab may be a viable option in recurrent ovarian cancer: A retrospective study.
Demirkiran, Aykut; Eryilmaz, Melek Karakurt; Karaagac, Mustafa; Araz, Murat; Korkmaz, Mustafa; Koçak, Mehmet Zahid; Artac, Mehmet.
Afiliación
  • Demirkiran A; Department of Medical Oncology, Necmettin Erbakan University School of Medicine, Akyokus, Konya, Turkey.
  • Eryilmaz MK; Department of Medical Oncology, Necmettin Erbakan University School of Medicine, Akyokus, Konya, Turkey.
  • Karaagac M; Department of Medical Oncology, Necmettin Erbakan University School of Medicine, Akyokus, Konya, Turkey.
  • Araz M; Department of Medical Oncology, Necmettin Erbakan University School of Medicine, Akyokus, Konya, Turkey.
  • Korkmaz M; Department of Medical Oncology, Necmettin Erbakan University School of Medicine, Akyokus, Konya, Turkey.
  • Koçak MZ; Department of Medical Oncology, Necmettin Erbakan University School of Medicine, Akyokus, Konya, Turkey.
  • Artac M; Department of Medical Oncology, Necmettin Erbakan University School of Medicine, Akyokus, Konya, Turkey.
J Cancer Res Ther ; 19(3): 595-600, 2023.
Article en En | MEDLINE | ID: mdl-37470581
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas Tipo de estudio: Observational_studies / Risk_factors_studies Idioma: En Revista: J Cancer Res Ther Asunto de la revista: NEOPLASIAS / TERAPEUTICA Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas Tipo de estudio: Observational_studies / Risk_factors_studies Idioma: En Revista: J Cancer Res Ther Asunto de la revista: NEOPLASIAS / TERAPEUTICA Año: 2023 Tipo del documento: Article